首页> 外文期刊>Drugs - Real World Outcomes >Changes in Body Image in Patients with Prostate Cancer over 2?Years of Treatment with a Gonadotropin-Releasing Hormone Analogue (Triptorelin): Results from a Belgian Non-Interventional Study
【24h】

Changes in Body Image in Patients with Prostate Cancer over 2?Years of Treatment with a Gonadotropin-Releasing Hormone Analogue (Triptorelin): Results from a Belgian Non-Interventional Study

机译:促性腺激素释放激素类似物(Triptorelin)治疗2年以上的前列腺癌患者体内图像的变化:一项比利时非干预性研究的结果

获取原文
           

摘要

Background Androgen deprivation therapy has been associated with worsened body image in prostate cancer patients. Body image and physical presentation changes were investigated in patients receiving a gonadotropin-releasing hormone analogue (triptorelin) as part of treatment for locally advanced or metastatic prostate cancer. Objective The aim was to evaluate the changes in self-perception of the body and to assess the relationship of these changes over a period of 2?years in men treated with triptorelin as primary therapy for advanced or locally advanced prostate cancer. Methods Data were collected for 2?years in accordance with routine clinical practice. Body image was assessed using the body image scale (BIS). Patient body mass index (BMI) and waist circumference were also measured. Results BIS and BMI data for both baseline and a least one post-baseline visit were available for 98 of the 145?patients enrolled. The median change in BIS score for patients assessed around 12 or 24?months after baseline and at the last observation was zero, indicating no body image deterioration in at least half of patients. Statistically significant BIS score increases were detected in assessments around 6, 12 and 18?months, but not after 2?years, indicating some patients experienced body image deterioration at some point during treatment. Changes in BMI from baseline were modest and generally not statistically significant. Waist circumference increased during the study (mean?±?standard deviation increase of 1.00?±?5.01?cm at the last observation). Positive correlations were determined between increases in BIS score and both BMI and waist circumference ( r =?0.235 and 0.267, respectively; p =?0.020 and 0.008) at the last observation for all patients, as well as during the second year of the study. Conclusions Most patients did not experience clinically meaningful worsening of body image perception during the study. BMI and waist circumference had a modest impact on body image during study year 2.
机译:背景技术雄激素剥夺疗法已经与前列腺癌患者的身体形象恶化相关。在接受促性腺激素释放激素类似物(曲普瑞林)治疗局部晚期或转移性前列腺癌的患者中,研究了其身体图像和体格变化。目的目的是评估使用曲普瑞林作为晚期或局部晚期前列腺癌的主要治疗方法的男性在2年内的身体自我感知变化,并评估这些变化之间的关系。方法按照常规临床资料收集2年资料。使用人体图像比例(BIS)评估人体图像。还测量了患者的体重指数(BMI)和腰围。结果145名患者中有98名获得了基线和至少一次基线访视的BIS和BMI数据。在基线后约12或24个月以及最后一次观察时评估的患者的BIS评分中位数变化为零,这表明至少一半的患者没有身体图像恶化。在大约6、12和18个月的评估中检测到BIS评分有统计学显着性提高,但在2多年后才发现,表明某些患者在治疗过程中的某个时候出现了身体图像恶化。与基线相比,BMI的变化是适度的,通常没有统计学意义。在研究过程中腰围增加(在最后一次观察中,平均标准偏差增加1.00±±5.01μcm)。在所有患者的最后一次观察以及研究的第二年中,BIS评分的增加与BMI和腰围的增加之间呈正相关(r分别为0.235和0.267; p分别为0.020和0.008)。 。结论大多数患者在研究过程中并未经历有意义的临床意义上的身体意象恶化。在研究的第二年中,BMI和腰围对身体形象的影响不大。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号